Group 1 - The core viewpoint of the article highlights the strategic partnership between Suzhou Yusen Pharmaceutical Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. to develop innovative traditional Chinese medicine products [1] - The collaboration focuses on two innovative TCM products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules," aiming to enhance the research and industrialization of TCM [1] - The partnership aims to integrate technology, clinical, and industrial resources to cover the entire chain of preclinical research, clinical research, registration, and post-market promotion [1] Group 2 - Yusen Pharmaceutical emphasizes the combination of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. plans to deepen exploration in areas such as international registration of TCM and the development of health products [2] - The collaboration is expected to contribute to the construction of a Sino-Sichuan TCM innovation corridor, facilitating the global market entry of Chinese TCM new drugs [2]

Core Insights - Suzhou Yusen Pharmaceutical Development Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. signed a product cooperation agreement to collaborate on two innovative traditional Chinese medicine products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules" [1][2] - The partnership aims to enhance the research and industrialization of traditional Chinese medicine, integrating resources across technology, clinical research, registration, and post-market promotion [1][2] Group 1 - "Xiaoxian Zhihuan Oral Liquid" targets children aged 3-7 with adenoid hypertrophy, utilizing ingredients like Platycodon and Houttuynia to clear heat and resolve phlegm, filling a gap in the traditional Chinese medicine market [2] - "Tiandan Dingxuan Granules" is designed for treating dizziness caused by phlegm and wind, featuring core ingredients such as Gastrodia and Salvia, addressing the growing demand for dizziness treatment in an aging population [2] - Both products are expected to enter clinical trials by 2026, targeting a market of 4 billion for adenoid hypertrophy and 1.2 billion for dizziness, showcasing the unique characteristics of traditional Chinese medicine with minimal side effects [2] Group 2 - The collaboration is seen as a synergy of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Future plans include exploring international registration of traditional Chinese medicine and the development of health products, contributing to the construction of a collaborative innovation corridor between Sichuan and Suzhou [2]